Savara Raises $47 Million in Stock and Warrant Deal

Edward Kim  |

We first highlighted Savara (Nasdaq: SVRA) in this space in July 2017 as a company worth watching in the pulmonary disease market. Savara raised $47 million in gross proceeds this week in a follow-on offering of common stock and warrants. The company sold 5.25 million common shares at $7.85 and warrants to an existing investor to purchase 775,000 shares of common at $7.84 per warrant - $7.85 minus the one cent exercise price per each pre-funded warrant.

The company has made notable clinical and corporate progress since July, which has fueled a 40% rally in the stock during the period:

  • Initiated its Phase III, randomized, double-blind, placebo-controlled study of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF).
  • Completed patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial of Aironite, a sodium nitrite solution for inhalation via nebulization, in patients with heart failure with preserved ejection fraction (HFpEF).
  • Uplisted to the Nasdaq Global Select Market


Source: Savara

Upcoming Milestones

Though the company has two candidates - Molgradex and AeroVanc - that are further along in clinical trials, it's the progress of Aironite that investors will be tracking as it's the next clinical candidate for which any top line results will be available. Expect those in the first half of 2018.

Source: Savara

We note that the follow-on offering was priced yesterday morning at a significant discount to Tuesday's $9.21 close - a reasonable haircut considering the stock's relatively light volume. Encouragingly, the stock has traded steadily at a premium to the offering price over the past two days. We'll continue to keep close watch on Savara's clinical progress.

Please email us at to see our Case Studies and Testimonials.

Please click here for information on our new trading platform.

Please click here to see our weekly newsletter.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
SVRA Savara Inc. 2.42 -0.02 -0.82 445,199 Trade



Symbol Last Price Change % Change






INTERVIEW: CEO Dr. Martin Eaton - Heads Up Checkup Host & Contributor Silvia Davi interviewing CEO of Heads Up Checkup, Dr. Martin Eaton.